SWITZERLAND/UK: LONZA, CELLTECH COOPERATE
Article Abstract:
Lonza Biologics and Celltech Therapeutics Ltd of Slough, UK, are to cooperate in the production of the anti-TNF antibody product CDP 571 for the treatment of Crohn's disease on the basis of mammal cultures. The two partners are to carry out process validation studies for a Biologics Licence Application with the US Food and Drug Administration.
Publication Name: Chemische Rundschau
Subject: Pharmaceuticals and cosmetics industries
ISSN: 0009-2983
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
SWITZERLAND/US: CANCER R&D DEAL BY ROCHE, BMS
Article Abstract:
The two agents Herceptin and Taxol for the treatment of breast cancer are to be tested jointly in common clinical studies by Bristol-Myers Squibb and Roche.
Publication Name: Chemische Rundschau
Subject: Pharmaceuticals and cosmetics industries
ISSN: 0009-2983
Year: 2000
User Contributions:
Comment about this article or add new information about this topic:
SWITZERLAND/UK: ROCHE/VERNALIS DEVELOPING TOGETHER
Article Abstract:
Swiss Basle-based Roche group and British Vernalis are cooperating in the clinical testing of an anti-obesity drug which they had researched together. The clinical studies are to start at the end of 2001. In addition to its payments due to Vernalis, Roche will have to pay license fees once the drug is approved of by the authorities.
Publication Name: Chemische Rundschau
Subject: Pharmaceuticals and cosmetics industries
ISSN: 0009-2983
Year: 2001
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: SWITZERLAND/UK: ARES SERONO, BRITISH BIOTECH R&D. AUSTRIA: SANOCHEMIA BOOSTS SYNTHESIS. SWEDEN: REMYNIL BY SANOCHEMIA
- Abstracts: SWITZERLAND: STERITEC BOUGHT BY SULZER INFRATEC. GERMANY: VINTRON INVESTING IN VINYL CHLORIDE. South Africa/Germany: Lurgi, Sasol team up
- Abstracts: Germany: BioTissue sole owner of Trans-Tissue. GERMANY: HENKEL SUPPORTS TEST KIT DEVELOPER. GERMANY: BIO-CARE TO LAUNCH EPIGRAFT